Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522224 | 0.76 | ALDH1A1 (0.34) | GAAKDM4EPOLBALDH1A1KMT2A | |
| SCHEMBL3192482 | 0.69 | KDM4E (0.84) | GAAKDM4EPOLBALDH1A1CA1 | |
| SCHEMBL4470800 | 0.69 | GAA (1.00) | GAAKDM4EPOLBALDH1A1CA1 | |
| SCHEMBL3523595 | 0.68 | ALDH1A1 (0.42) | POLBALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3522165 | 0.68 | ALDH1A1 (0.48) | GAAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL6631803 | 0.60 | KCNH2 (0.58) | GAAALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23375458 | 0.59 | ALDH1A1 (0.78) | GAAKDM4EPOLBALDH1A1CA1 | |
| SCHEMBL4903379 | 0.59 | POLB (0.75) | GAAKDM4EPOLBALDH1A1CA1 | |
| SCHEMBL1647857 | 0.59 | ALDH1A1 (0.69) | GAAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL11406971 | 0.59 | KMT2A (0.53) | GAAKDM4EPOLBALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | GAA 1386/4885KDM4E 3806/4885POLB 1067/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | GAA 1288/4885KDM4E 3935/4885POLB 726/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | GAA 1386/4885KDM4E 3806/4885POLB 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.